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A major drawback of chemotherapy is the lack of specific toxicity
towards cancer cells which leads to important side-effects that
prevent the treatment from achieving tumour reduction. One
strategy that could overcome this problem is to introduce into
malignant cells a gene encoding an enzyme that sensitizes them to
chemotherapeutic agents. Since the first experiments using the
herpes simplex virus thymidine kinase (HSV-TK) (Moolten, 1986;
Moolten and Wells, 1990) which activates the acyclic nucleoside
analogue ganciclovir (GCV) intratumourally, various drug sensi-
tivity genes (‘suicide genes’) have been reported (Mullen et al,
1992; Huber et al, 1993; Wei et al, 1994; Chen et al, 1995; Parker
et al, 1997).
A critical point of this strategy is the limiting gene transfer effi-
ciency to the tumour mass. However, the ability of a toxic anabo-
lite, metabolically converted in the transfected cells, to diffuse into
neighbouring untransfected cells could alleviate the problem. This
‘bystander effect’ has been observed in many cancer gene therapy
experiments, and reduction of tumour mass was observed even
when a small percentage of cancer cells were genetically modified
(Freeman et al, 1993; Chen et al, 1995). The bystander effect is
achieved by diffusion of phosphorylated nucleosides through gap
junctions in the HSV-TK/ganciclovir system (Fick et al, 1995).
However, experiments with other suicide genes, such as cytosine
deaminase which cleaves 5-fluorocytosine to 5-fluorouracil (5-
FU), have shown the advantages of a diffusible, gap junction-
independent bystander effect (Huber et al, 1994; Trinh et al, 1995;
Denning and Pitts, 1997).
Thymidine phosphorylase (EC 2.4.2.4) (TP), also described as
the angiogenic platelet-derived endothelial cell growth factor (PD-
ECGF) (Ishikawa et al, 1989; Moghaddam and Bicknell, 1992;
Sumizawa et al, 1993; Miyadera et al, 1995), is a homodimeric
enzyme with a monomeric molecular mass of about 55 kDa
(Desgranges et al, 1981; Miyazono et al, 1987) and which phos-
phorolytically cleaves thymidine to yield thymine and deoxyribose
1-phosphate (Friedkin and Roberts, 1953; Krenitsky, 1968). TP is
expressed in various human cells and tissues and plays a role in
plasma thymidine homeostasis (Zimmerman and Seidenberg,
1964; Shaw et al, 1988; Fox et al, 1995). The levels of expression
in different human tissues can vary up to 15-fold (Yoshimura et al,
1990). Moreover, TP levels are increased in several types of
malignant tumours when compared to the non-neoplastic regions
of these tissues (Obrien et al, 1996), and also in the plasma from
tumour-bearing animals and cancer patients (Luccioni et al, 1994).
TP is also a key enzyme in the metabolic activation of fluoro-
pyrimidines that share the physiological pathway of pyrimidines.
TP is responsible for the conversion of 5¢-deoxy-5-fluorouridine
(5¢-DFUR, doxifluridine) to 5-FU and, because of its reversible
phosphorolytic activity, assumes also the conversion of 5-FU to its
anabolite 5-fluoro-2¢-deoxyuridine (5-FdUrd). Transfection exper-
iments have provided evidence that TP mediates the sensitivity of
HT-29 human colon carcinoma cells to 5-FU (Schwartz et al,
1995), and of MCF-7 human breast cancer cells to 5¢-DFUR
(Patterson et al, 1995). Furthermore, the induction of TP expres-
sion by interferon increases 5-FU cytotoxicity (Schwartz et al,
1994, 1998) and recent studies suggest that the level of TP activity
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Summary 5-Fluorouracil (5-FU) and 5¢-deoxy-5-fluorouridine (5¢-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine
phosphorylase (TP). Transfecting the human TP cDNA into cancer cells in order to sensitize them to these pyrimidine antimetabolites may be
an important approach in human cancer gene therapy research. In this study, an expression vector containing the human TP cDNA (pcTP5)
was transfected into LS174T human colon carcinoma cells. Eight stable transfectants were randomly selected and analysed. The cytotoxic
effects of 5-FU and 5¢-DFUR were higher in TP-transfected cells as compared to wild-type cells. The maximal decreases in the IC50 were 80-
fold for 5-FU and 40-fold for 5¢-DFUR. The increase in sensitivity to these pyrimidines of TP-transfected cells significantly correlated with the
increase in both TP activity and TP expression. Transfected clone LS174T-c2 but not wild-type cells exhibited formation of [3H]FdUMP from
[3H]5-FU. In addition the LS174T-c2 clone enhanced the cytotoxic effect of 5¢-DFUR, but also that of 5-FU, towards co-cultured parental cells.
For both anti-cancer agents, this bystander effect did not require cell–cell contact. These results show that both 5-FU or 5¢-DFUR could be
used together with a TP-suicide vector in cancer gene therapy.
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Correspondence to: P Cuqcould be a prognostic marker for the 5-FU cytotoxicity in vitro and
in vivo (Fox et al, 1997; Griffiths and Stratford, 1997; Mader et al,
1997). In a recent paper, we have demonstrated an increased 5-FU
sensitivity of a murine adenocarcinoma cell line in vitro and
in vivo after transfection of TP cDNA (Evrard et al, 1999).
Therefore, TP gene transfer in cancer cells in order to enhance
their sensitivity to fluoropyrimidines could be a promising strategy
in cancer gene therapy.
In this report, we investigated the effect of TP overexpression in
human LS174T colorectal cancer cells on [3H]5-FU metabolism
and on 5-FU and 5¢-DFUR sensitivity. We next examined the
bystander effect on neighbouring untransfected cells in contact and
non-contact conditions.
MATERIALS AND METHODS
Chemicals
5-FU, 5¢-DFUR, enhanced chemiluminescence (ECL) reagents
(luminol, hydrogen peroxide and coumaric acid) and high-perfor-
mance liquid chromatography (HPLC) reagents were from Sigma
(St Quentin Fallavier, France). [H3]5-FU (12.5 Ci mmol–1) was
from Du Pont de Nemours (Les Ulis, France).
Cell lines
The human colorectal adenocarcinoma LS174T cells (ATCC
number, CL-188) were cultured at 37°C in a fully humidified 5%
carbon dioxide atmosphere in RPMI-1640 medium supplemented
with 10% fetal calf serum (FCS) and 2 mM glutamine. COS-7 cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 5% FCS and 2 mM glutamine.
Human TP cDNA subcloning
The TP cDNA was kindly provided by Dr Rangana Choudhuri
(Imperial Cancer Research Fund, University of Oxford, UK). The
full-length human TP cDNA was obtained by digesting the
parental pPL5 vector with XbaI and HindIII and the insert was
ligated into the same sites of the mammalian expression vector
pcDNA3 (Invitrogen, NV Leek, The Netherlands) to produce
pcTP5. This vector was then transformed into cells (Escherichia
coli, DH5a) and the plasmid DNA purified using a Qiagen
Plasmid Kit (Qiagen, Courtaboeuf, France).
Transfection of human TP cDNA in COS-7 cells and
LS174T cells
COS-7 and LS174T cells (1 ´ 106 per 20 cm2 Petri dish) were
cultured for 24 h until cells were approximately 80% confluent.
They were then transfected with pcTP5 or pcDNA3 (control) using
the Lipofectamine™ reagent (Life Technologies, Cergy-Pontoise,
France) using conditions as recommended by the
manufacturer. After 48 h incubation, COS-7 cells were lysed and
assayed for TP activity and expression. Stable LS174T/pcTP5
transfectants were selected for geneticin (G418 sulphate, Life
Technologies, Cergy-Pontoise, France) resistance (250 mg ml–1
culture medium), and eight clones were randomly selected and
analysed for 5-FU and 5¢-DFUR sensitivity, TP activity and
protein expression.
Cell lysis
Cells (COS-7 or LS174T) were homogeneized on ice in 100 ml of
a lysis buffer containing 50 mM Tris–HCl (pH 8.0), 150 mM
sodium chloride, 100 mg ml–1 phenylmethylsulphonyl fluoride
(PMSF), 1 mg ml–1 aprotinin and 1% Triton X-100. The lysates
were centrifuged at 20 000 g for 30 min at 4°C and protein level of
the supernatants was determined according to Bradford (1976).
Immunoblotting and immunocytostaining
The mouse monoclonal IgG1 654-1 raised against human TP was
kindly provided by Nippon Roche Research Center (Nishida et al,
1996) and was used as primary antibody for either immunoblotting
or immunocytostaining experiments. For immunoblotting, super-
natant proteins (20 mg) of cell lysates, obtained as described above,
were separated on sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE). The proteins were electroblotted onto
nitrocellulose membrane, and incubated with 0.2 mg ml–1 of
primary antibody followed by horseradish peroxidase-conjugated
goat anti-mouse IgG (Sigma, St Quentin Fallavier, France).
Immunolabelled proteins were vizualized using X-ray film after
incubation with ECL reagents. For immunocytostaining, cells were
seeded on cover-slips in 12-well plates. After fixing with methanol
and permeabilization with phosphate-buffered saline (PBS)–0.1%
Triton, cells were incubated with 1 mg ml–1 of primary antibody
followed by fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse IgG (Sigma, St Quentin Fallavier, France).
TP activity assay
The enzyme activity in cell lysates was assayed as previously
described (Yoshimura et al, 1990), with minor modifications.
Briefly, 50 ml of supernatants were added to 150 ml of a reaction
mixture consisting of 10 mM thymidine, 10 mM KH2PO4 (pH 8.4)
and then incubated at 37°C for 4 h. The reaction was stopped by
the addition of 800 ml of 0.2 N sodium hydroxide. The absorbance
at 300 nm was determined and the amount of thymine in the
reaction mixture was calculated using a calibration curve. The
TP activity was expressed as pmol thymine–1 mg protein–1 h–1.
[3H]5-FU metabolism analysis
Cells (2 ´ 106) were seeded in a 25 cm2 flask and were treated for
4 h with 100 mCi of [3H]5-FU (corresponding to a final concentra-
tion of 1.6 mM). Cells were then harvested and vortexed in 60%
methanol. After methanol evaporation, the mobile phase (100 ml)
was added to the residue for HPLC injection. Chromatographic
conditions were as follows: reverse phase column, Licrosphere C8,
5 mm; mobile phase, buffer pH 7 10% (1.7 mM K2HPO4, 5 mM
tetrabutylammonium nitrate): methanol 90%; flow rate 1 ml min–1;
isocratic conditions. Detection was performed using a radiometric
detector (Flo-One Beta Radiomatic, Packard Instrument SA) and
peaks identified by comparing retention times with standards.
In vitro cytotoxicity assay
The effect of anticancer agents (5-FU, 5¢-DFUR) on cell viability
was assessed using the neutral red assay as previously described
(Evrard et al, 1996). Briefly, aliquots of cell suspension (5 ´103cells
per well) were seeded in 96-well microtitre plates which were incu-
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bated for 24 h at 37°C in a fully humidified atmosphere of 5%
carbon dioxide in air. The cells were then incubated for 72 h in the
absence (control) or the presence of different drug concentrations
(150 ml in fresh medium per well, eight wells per agent concentra-
tion). Thereafter, cells were washed with PBS and 150 ml of a
neutral red solution (40 mg ml–1) was added. After 3 h at 37°C, 5%
carbon dioxide, the cells were washed with PBS and destained with
150 ml of glacial acetic acid (1%)–ethanol (50%) (v/v). Absorbances
at 540 nm (A540) were measured using a microplate reader
(Labsystems Multiscan MS). The effect of the drugs on cell survival
was expressed as a growth ratio calculated using the equation A540
drug-treated/A540 control.
Assessment of in vitro bystander effect
TP-transfected LS174T-c2 cells and parental cells were mixed in
various ratios [c2 cells/(c2 cells + parental cells)] and seeded
5 ´ 103 cells ml–1 in 96-well plates. After 24 h at 37°C, the cells
were incubated for 3 days in the absence (control) or the presence
of different drug concentrations (0.01–100 mM) and the neutral red
uptake assay was performed as described above. The results are
expressed as a growth ratio relative to drug-free controls. To study
the requirement of direct cell–cell contact for the bystander effect,
parental LS174T cells were seeded in the bottom chamber of 96-
well microtitre plates (5 ´ 103 cells per well) and parental or
LS174T-c2 cells (5 ´ 103 cells per insert) were placed in the top
chamber of membrane culture inserts (Anopore membrane, pore
size 0.02 mM, Nunc, France). After a 24 h incubation at 37°C, cells
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Figure 1 Human thymidine phosphorylase expression and activity in COS-
7 and LS174T cells. Upper panel: lysates from parental (wt) or pcTP5-
transfected (TP) COS-7 cells, and from parental (wt) or pcTP5-transfected
LS174T cell clones (c1 to c8) were incubated at 37°C for 4 h in the presence
of 10 mM thymidine. The 300 nm absorbance and the amount of thymine
were calculated as described above; the TP activity was expressed as pmol
thymine mg protein–1 h–1. Data are means ± s.e.m. of three separate
experiments. Lower panel: proteins from COS-7 and LS174T cell lysates
were separated by SDS-PAGE and electroblotted onto nitrocellulose sheets.
The human TP immunoreactivity was assessed using anti-human TP IgG
AB
CD
Figure 2 Immunocytostaining of human TP in LS174T cells. Immunocytostaining was performed using mouse monoclonal IgG raised against human TP as
described in Materials and Methods. Phase contrast microscopy: (A) parental LS174T cells, (B) LS174T-c2 cells; fluorescence microscopy: (C) parental LS174T
cells, (D) LS174T-c2 cells. Magnification ´ 200Fluoropyrimidines cytotoxicity enhancement by thymidine phosphorylase 1729
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were treated for 72 h with different concentrations of 5-FU or 5¢-
DFUR (0.1–100 mM) which were added into the membrane culture
inserts. Thereafter, the membrane culture inserts were removed
and the survival of parental cells seeded in the microtitre plates
was measured as described above.
RESULTS
Subcloning of the human TP cDNA
In order to transfect the human TP cDNA in mammalian tumour
cells, we subcloned the full-length cDNA in the mammalian
expression vector pcDNA3 in a sense orientation with respect to
the CMV promoter. The functionality of pcTP5 was assessed by
studying the protein expression and the enzyme activity in lysates
from COS-7 cells transfected with the plasmid. As shown in
Figure 1, a strong and specific production of immunodetectable
human TP and a high TP activity were evident in pcTP5-trans-
fected cell lysates. An endogeneous TP activity was found in wild-
type COS-7 cells but the protein was not detected because the
anti-TP antibody is specific for human and not simian TP.
Expression of human TP in LS174T cells
Human adenocarcinoma LS174T cells were transfected with the
pcTP5 and stable transfectants were selected for geneticin resistance.
The growth rate of the transfected LS174T cells did not significantly
vary from that of the wild-type cells or that of pcDNA3-transfected
cells (data not shown). Eight clones of pcTP5-transfected cells (c1 to
c8) were randomly selected and analysed for TP activity and expres-
sion. The levels of enzyme activity, ranging from 0 to 730 pmol–1
mg–1 h–1, were closely related to protein expression as shown by
Western blot experiments (Figure 1). The parental cells expressed
neither immunodetectable TP nor significant TP activity. Clone 2
(LS174T-c2), which exhibited the highest TP protein expression and
activity (Figures 1 and 2), was used for analysis of the bystander
effect and [3H]5-FU metabolism.
[3H]5-FU metabolism
The increase expression of functional TP in LS174T-c2 cells
would lead to a greater metabolic activation of 5-FU to deoxy-
ribonucleotides. To address this, parental and LS174T-c2 cells
were incubated in the presence of [3H]5-FU and the resulting
metabolites were identified by HPLC coupled to a radiometric
detection. As shown in Figure 3, a significant amount of [3H]5-
fluorodeoxyuridine-monophosphate (5-dFUMP) accumulated in
LS174T-c2 cells but not in parental cells, whereas similar levels of
[3H]ribonucleotides (FUrd, FUMP, FUDP, FUTP) were detected in
both cell lines. Thus, TP-transfected cells displayed [3H]5-FU acti-
vation through both desoxyribonucleotides and ribonucleotides
pathways, whereas [3H]5-FU was exclusively activated through
the ribonucleotides pathway in parental cells.
In vitro cytotoxicity
The effect of human TP expression on the sensitivity of LS174T
cells to 5-FU and 5¢-DFUR was studied by using the neutral red
uptake assay. 5-FU and 5¢-DFUR decreased the cell viability in a
concentration-dependent fashion. The results expressed as IC50 are
shown in Table 1. The sensitivity to the fluoropyrimidines of
LS174T cells transfected with pcDNA3 was not significantly
different from that of parental cells. On the other hand, TP-
expressing LS174T cells were more sensitive to the cytotoxic
actions of 5-FU and 5¢-DFUR than the parental cells. Clones 2 and
Table 1 Sensitivity to 5-FU and 5¢-DFUR of LS174T cells wild-type and TP-
transfected clones
5-FU 5¢-DFUR
LS174T IC50 (mM) -Fold IC50(mM) -Fold
Wild-type 25.33 ± 0.87 1.0 10.92 ± 0.84 1.0
pcDNA3 25.67 ± 0.23a 1.0 10.52 ± 0.76a 1.0
Clone 1 0.68 ± 0.11 37.2 0.84 ± 0.08 13.0
Clone 2 0.32 ± 0.01 79.2 0.27 ± 0.03 40.4
Clone 3 4.69 ± 0.87 5.4 3.54 ± 0.71 3.1
Clone 4 2.12 ± 0.19 11.9 2.36 ± 0.23 4.6
Clone 5 0.29 ± 0.03 87.3 0.30 ± 0.03 36.4
Clone 6 25.94 ± 4.43a 1.0 9.84 ± 0.73a 1.1
Clone 7 9.36 ± 1.26 2.7 8.45 ± 1.18a 1.3
Clone 8 0.59 ± 0.07 42.9 0.65 ± 0.07 16.8
aNot significantly different when compared to wild-type cells, other values are
significant with P < 0.01 (Student’s t-test). IC50s were determined using the
neutral red assay. Each value represents the mean ± s.e.m. of three separate
experiments.
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Figure 3 Metabolism of [3H]5-FU in LS174T cells. Parental (A) or clone 2
(B) LS174T cells were incubated for 4 h in the presence of 100 mCi [3H]5-FU
(final concentration: 1.6 mM) and the resulting metabolites were identified by
HPLC coupled to a radiometric detection. Data are from one representative
experiment1730 A Evrard et al
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5 were found to be approximately 80-fold and 40-fold more sensi-
tive to 5-FU and 5¢-DFUR respectively. Moreover, there was a
significant correlation between the TP activity of the cell clones
and their in vitro sensitivity to 5-FU and 5¢-DFUR (r 2 = 0.9 and
0.85 respectively) (Figure 4A,B).
Bystander effect
Mixed cultures of parental and TP-transfected cells were generated
to study the involvement of a bystander effect in the in vitro cyto-
toxicity of 5-FU and 5¢-DFUR. When parental LS174T cells were
co-cultured with LS174T-c2 cells at a ratio of 0.1, the IC50 values
of 5-FU and 5¢-DFUR were lowered approximately tenfold, indi-
cating a clear bystander effect (Figure 5 A, B). There were signifi-
cant bystander effects (50% cell death) for both anticancer agents
(5 mM final concentration) even when only 5% of cells were trans-
fected (Figure 5 C, D).
We next investigated whether this bystander effect would
require direct cell–cell contact. The sensitivity to 5-FU of parental
cells was significantly higher when they were co-cultured, as
described above, with LS174T-c2 cells rather than with parental
cells in the culture inserts (Figure 6A). Similar results were
obtained with 5¢-DFUR (Figure 6B).
DISCUSSION
Despite the extended use of fluoropyrimidines, in particular 5-FU,
in advanced colorectal cancer, response rates are only 10–20%
TP activity (pmol
–1 mg
–1 h
–1)
0 200 400 600 800 0 200 400 600 800
4
3
2
1
0
4
3
2
1
0
1
/
i
C
5
0
A B
Figure 4 Correlation between TP activity and 5-FU (A) or 5¢-DFUR (B)
cytotoxicity in TP-transfected LS174T cell clones. TP activity and 1/IC50 were
significantly correlated for both 5-FU (r 2 = 0.9) and 5¢-DFUR (r 2 = 0.85). Data
are means of three separate experiments
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Figure 5 Bystander effect of 5-FU and 5¢-DFUR. The cell viability was studied by using the neutral red assay. Upper panel: TP-transfected LS174T cells (clone
2) were mixed and co-cultured with parental cells at various ratio (l l = 0, n n = 0.1, s s = 0.2, ´ = 0.5, • = 1) and then incubated in the presence of 5-FU (A) or 5¢-
DFUR (B). Lower panels: Effect of 5 mM 5-FU (C) or 5¢-DFUR (D) on co-cultured parental and LS174T-c2 cells at various ratios. Open bars, theoretical growth
ratio; solid bars, observed growth ratio. Data are means ± s.e.m. of eight wells from a microtiter plate columnFluoropyrimidines cytotoxicity enhancement by thymidine phosphorylase 1731
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(Cohen et al, 1993). Different strategies, including combination of
5-FU with other cytotoxic agents or with cytokines, are invoked to
increase the sensitivity of cancer cells to fluoropyrimidines (Elias
and Crismann, 1988; Schwartz et al, 1994). A new gene transfer
approach is based on the fact that 5-FU and 5¢-DFUR, a prodrug of
5-FU, are activated by TP. Thus, transferring the gene encoding
human TP into cancer cells could render them more susceptible to
5-FU and/or 5¢-DFUR. In this report, we examined the effects of
TP gene transfer in human colon cancer cells LS174T and their
subsequent sensitivity to fluoropyrimidines.
The human colon adenocarcinoma cell line LS174T was chosen
for establishing stable transfectants. Neither TP activity nor TP
expression were detectable in parental LS174T cells. Therefore,
LS174T cell line was an ideal model for studying the effects of TP
overexpression on colonic cancer cells sensitivity to fluoropyrim-
idines. From the selected TP-transfected cell clones, we observed
a good correlation between protein expression and TP activity
levels. Clone LS174T-c2, which exhibited the highest TP activity,
was chosen for [3H]5-FU metabolic profile analysis and bystander
effect experiments.
5-FU has been reported to be activated through two distinct path-
ways (Rustum et al, 1997; Sobrero et al, 1997). The first, initiated
by 5-FU conversion to 5-fluorouridine (FUrd) by uridine phos-
phorylase (UP), leads to fluororibonucleotides incorporation into
RNA. The second, initiated by 5-FU conversion to 5-fluoro-2¢-
deoxyuridine (FdUrd) by thymidine phosphorylase, leads to
thymidylate synthase inhibition by 5-fluoro-2¢-deoxyuridine mono-
phosphate (FdUMP) and to fluorodeoxyribonucleotides incorpora-
tion into DNA. HPLC analysis of [3H]5-FU metabolism was
carried out to evaluate the relative importance of the two pathways
in parental LS174T and LS174T-c2 cells. Parental LS174T cells
displayed an accumulation of [3H]fluororibonucleotides (FUrd,
FUMP, FUDP, FUTP) reflecting the exclusive activation of [3H]5-
FU by the ribonucleotides pathway. In agreement with the meta-
bolic profile, parental LS174T cells did not express thymidine
phosphorylase activity whereas a significant endogeneous uridine
phosphorylase activity was detected (data not shown). In contrast,
beside the synthesis of [3H]fluororibonucleotides, a strong forma-
tion of [3H]FdUMP was detected in TP-transfected LS174T-c2
cells. Similarly, Shwartz et al (1995) reported a correlation of TP
activity with FdUMP levels in human colon carcinoma HT-29 cells.
The first anabolite after 5-FU activation by TP, i.e. [3H]FdUrd, was
not detected in transfected cells, suggesting that the conversion of
FdUrd to FdUMP by thymidine kinase is not a limiting step and
occurs rapidly. This result, as previously suggested (Mader et al,
1997), argues against a decisive role of thymidine kinase in the
activation of 5-FU. In conclusion, these data clearly indicate that
TP is able to activate 5-FU when overexpressed in LS174T cancer
cells.
We next assessed the in vitro sensitivity to 5-FU and 5¢-DFUR
of parental and TP-transfected LS174T cells. The cytotoxicity of
both 5-FU and 5¢-DFUR was enhanced by TP expression; cell
sensitivity and TP activity were correlated highly. The maximal
decreases in the IC50 values observed with LS174T-c2 cells were
80-fold for 5-FU and 40-fold for 5¢-DFUR. Such a significant
increase of both fluoropyrimidines cytotoxic effects by TP gene
transfer into human cancer cells has never been reported so far.
Schwartz et al (1995) reported a lower enhancement (19-fold) of
human colon cancer cells (HT-29) sensitivity to 5-FU by TP trans-
fection. Other works have shown that TP transfection in MCF-7
(Patterson et al, 1995) or PC-9 (Kato et al, 1997) cells increased
the sensitivity to 5¢-DFUR but not to 5-FU. This discrepancy could
be explained by a higher sensitivity of the parental cells to 5-FU
correlated to an endogenous TP activity. Therefore, parental
LS174T cells which exhibit no TP activity were relatively resistant
to 5-FU despite activation of 5-FU by UP. Activation of the
desoxyribonucleotides pathway by TP overexpression in LS174T
cells greatly enhanced 5-FU cytotoxicity. Our data are consistent
with previous reports proposing TP as a biochemical determinant
of response to 5-FU and suggest that the loss of TP activity could
be responsible for 5-FU resistance (Chu et al, 1990; Schwartz et al,
1995; Fox et al, 1997; Mader et al, 1997).
By contrast, parental LS174T displayed high sensitivity to 5¢-
DFUR when compared to PC-9 (Kato et al, 1997) or KB
(Haraguchi et al, 1993) cancer cell lines. Since LS174T cells
express significant UP activity but no TP activity, 5¢-DFUR may
be efficiently activated by the endogeneous UP. After TP transfec-
tion, LS174T-c2 clones were found to be 40-fold more sensitive to
5¢-DFUR than parental cells. This result strongly suggests that
metabolic activation of 5¢-DFUR is achieved by both TP and UP in
cancer cells. Therefore, a cancer gene therapy approach using 5¢-
DFUR as prodrug and TP as a suicide gene should account for
basal TP activity and also basal UP activity of tumour cells.
The increased sensitivity to 5-FU and 5¢-DFUR of TP trans-
fected LS174T cells has led us to examine the neighbouring cyto-
toxicity on adjacent, untransfected cells. In agreement with
previous reports (Patterson et al, 1995; Kato et al, 1997), we
describe here a bystander effect with 5¢-DFUR and, moreover, we
demonstrate for the first time a bystander effect with 5-FU. In our
experiments, a TP-transfected cell ratio of 0.05 is sufficient to
obtain 50% cell death and a ratio of 0.2–0.3 is sufficent for a
maximal effect on the whole cell population in the presence of 5 mM
5-FU or 5¢-DFUR.
Depending on the suicide gene, the bystander effect can be
achieved by diffusion of activated anabolites from transfected to
untransfected cells in a cell–cell contact-dependent (Fick et al, 1995)
or -independent (Huber et al, 1994; Chen and Waxman, 1995; Kato
et al, 1997) fashion. [3H]5-FU metabolic profile analysis demon-
strated high level of FdUMP in TP-transfected but not in parental
LS174T cells. However, this phosphorylated compound is not
diffusible and a bystander effect could occur through gap junctions as
is the case for phosphorylated derivatives of ganciclovir. As 5-FdUrd
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Figure 6 Diffusibility of the bystander effect. Parental and TP-transfected
(clone 2) LS174T cells were co-cultured in non-contact conditions as
described above. The viability of parental cells, seeded on the lower chamber
and co-cultured with parental cells (l l) or TP-transfected cells (•) in the
culture inserts, was assessed using the neutral red assay after exposure to
5-FU (A) or 5¢-DFUR (B). Data are means ± s.e.m. of eight wells from a
microtiter plate column1732 A Evrard et al
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is able to cross the cell membrane through an in-and-out nucleoside
transport (Grem and Fisher, 1986; Lonn et al, 1989) we suggest that
5-FdUrd, although not detected in HPLC experiments, could be
responsible for the diffusible bystander effect observed in cytotoxi-
city assays in non-contact conditions.
We are aware of the angiogenic effect of TP and of the potential
resulting tumour growth enhancement. However, we think that it
does not compromise its use as a suicide gene because TP-trans-
fected cells would not be able to promote angiogenesis in so far
as they would be selectively killed by the fluoropyrimidine
chemotherapy. On the other hand, a transient expression of TP in
target cells could overcome this problem.
In conclusion, our data suggest that level of TP activity is
strongly implicated in the 5¢-DFUR but also 5-FU sensitivity of
human colon carcinoma cells. Therefore TP should be considered
as a potential suicide gene for cancer gene therapy with 5-FU or 5¢-
DFUR. High gene transfer efficiency and specific targeting of TP
gene in tumour cells could be achieved by using recombinant viral
vectors and promoter elements of genes usually transcribed by
tumours such as carcinoembryonic antigen in colon carcinoma.
Furthermore, our results have a direct clinical relevance, especially
since a number of 5-FU prodrugs such as capecitabine, activated
by TP, are in clinical trials. Thus, these data should provide a basis
for measuring TP in clinical material and correlate with outcome
of fluoropyrimidine-based therapy.
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